Quantcast

Latest Rosuvastatin Stories

2010-11-29 11:00:00

Patent filing is based on synergistic findings suggesting enhanced plaque management with RVX-208 in combination with statins TSX Exchange Symbol: RVX CALGARY, Nov. 29 /PRNewswire-FirstCall/ - Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) is pleased to announce today that it has filed additional new patent protection based on novel findings derived from its recently completed ASSERT Phase 2 clinical trial. A new patent application has been filed for novel dosing...

2010-11-18 09:00:00

BURLINGTON, Mass., Nov. 18, 2010 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that in the treatment of dyslipidemia, surveyed cardiologists and primary care physicians (PCPs) now perceive AstraZeneca's Crestor's ability to reduce mortality comparable to Pfizer's Lipitor. This finding has changed from Decision Resources' 2009 analysis in which surveyed cardiologists viewed Lipitor as significantly...

2010-11-17 17:37:47

Widely prescribed for their cholesterol-lowering properties, recent clinical research indicates that statins can produce a second, significant health benefit: lowering the risk of severe bacterial infections such as pneumonia and sepsis. A new explanation for these findings has been discovered by researchers at the University of California, San Diego School of Medicine and Skaggs School of Pharmacy & Pharmaceutical Sciences, who describe for the first time how statins activate the...

2010-10-28 03:48:00

NEW YORK, Oct. 28 /PRNewswire/ -- See video from AstraZeneca at: http://www.thenewsmarket.com/CustomLink/CustomLinks.aspx?GUID=7c13a65b-0529-4b28-82e0-7ebe8b9d9f42&bhcp=1&alertid=226c94c1-b49b-45a9-b982-615158357500# Anglo-Swedish pharmaceutical company AstraZeneca announced that revenue for the third quarter declined by 2% at constant exchange rates (CER) to $7,898 million. Strong double-digit sales growth at CER for Crestor, Symbicort and Seroquel XR. Revenue in markets outside...

2010-10-27 07:00:00

MORRISTOWN, N.J., Oct. 27 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today confirmed that its subsidiary, Watson Laboratories, Inc., filed a new drug application under Section 505(b)(2) of the Federal Food and Drug Cosmetic Act (FFDCA) with the U.S. Food and Drug Administration (FDA) seeking approval to market rosuvastatin zinc 5, 10, 20 and 40 mg tablets. Watson's rosuvastatin zinc tablets are a new salt version of AstraZeneca's Crestor ®...

2010-09-28 20:58:08

Average C-reactive protein (CRP) values vary in diverse populations "” possibly impacting how doctors estimate cardiovascular risk and determine statin treatment, according to a new study in Circulation: Cardiovascular Genetics, a journal of the American Heart Association. CRP is a marker of inflammation, and high levels of it in the blood have been associated with a higher risk for heart disease. But it's uncertain if the association is causal. Statins are a class of...

2010-09-07 07:00:00

WILMINGTON, Del., Sept. 7 /PRNewswire/ -- AstraZeneca (NYSE: AZN) urges Americans to take important steps to manage their cholesterol during National Cholesterol Education Month in September. Based on current estimates, 102 million Americans aged 20 years or older have borderline high or high cholesterol.(i) Adopting a healthy lifestyle, including a low-fat diet and exercise, along with cholesterol medication if needed, can help lower levels of LDL or "bad" cholesterol.(ii,, iii, iv) To...

2010-08-24 15:00:00

Study highlights: -- People at intermediate risk of cardiovascular disease who have high levels of high sensitivity C-reactive protein (hsCRP), a blood marker for inflammation, could benefit from cholesterol-lowering therapy even if their cholesterol is already at desirable levels. -- Data indicates that people with only a 5 percent to 20 percent risk of having heart disease in the next ten years, but who have high levels of hsCRP could reduce the risk of heart attack and stroke by more...

2010-07-29 07:22:00

FLORHAM PARK, N.J., July 29 /PRNewswire/ -- Shionogi Inc., a U.S.-based group company of Shionogi & Co., Ltd., today announced the U.S. Food and Drug Administration approval of CUVPOSA(TM) (glycopyrrolate), the first liquid treatment for patients ages 3-16 who suffer from chronic severe drooling associated with neurologic conditions such as cerebral palsy. CUVPOSA(TM) was designated an Orphan Drug by the FDA. "The FDA approval of CUVPOSA provides parents and caregivers the first liquid...

2010-07-26 13:04:28

The European Society of Cardiology (ESC) is concerned that interpretations of a paper about cholesterol, published in the Lancet (1), could act to deter ongoing research efforts into developing new therapeutic strategies to increase high density lipoprotein (HDL) cholesterol.  Caution, the ESC experts advise, should be displayed in the interpretation of the results. In the Lancet study, Paul Ridker and colleagues, from Brigham and Women's Hospital (Boston, MA, USA), undertook a...


Word of the Day
sough
  • A murmuring sound; a rushing or whistling sound, like that of the wind; a deep sigh.
  • A gentle breeze; a waft; a breath.
  • Any rumor that engages general attention.
  • A cant or whining mode of speaking, especially in preaching or praying; the chant or recitative characteristic of the old Presbyterians in Scotland.
  • To make a rushing, whistling, or sighing sound; emit a hollow murmur; murmur or sigh like the wind.
  • To breathe in or as in sleep.
  • To utter in a whining or monotonous tone.
According to the OED, from the 16th century, this word is 'almost exclusively Scots and northern dialect until adopted in general literary use in the 19th.'
Related